http://orcid.org/0000-0001-6998-662X
References
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
- Patnaik MM, Gangat N, Knudson RA, et al. Chromosome 8p11. 2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. Am J Hematol. 2010;85:238–242.
- Parish A, Schwaederle M, Daniels G, et al. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle. 2015;14:2121–2128.
- Strati P, Tang G, Duose DY, et al. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymp. 2017 [Nov 9]; [5 p.]. DOI:10.1080/10428194.2017.1397663
- Perez Botero J, Chen D, Cousin MA, et al. Clinical characteristics and platelet phenotype in a family with RUNX1 mutated thrombocytopenia. Leuk Lymp. 2017;58:1963–1967.
- Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. JCO. 2012;30:3109–3118.
- Agerstam H, Lilljebjorn H, Lassen C, et al. Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome. Genes Chromosom Cancer. 2007;46:635–643.
- Buijs A, van Wijnen M, van den Blink D, et al. A ZMYM2-FGFR1 8p11 myeloproliferative neoplasm with a novel nonsense RUNX1 mutation and tumor lysis upon imatinib treatment. Cancer Genet. 2013;206:140–144.
- Landberg N, Dreimane A, Rissler M, et al. Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib. Eur J Haematol. 2017;99:442–448.
- Kreil S, Ades L, Bommer M, et al. Limited efficacy of ponatinib in myeloproliferative neoplasms associated with FGFR1 fusion genes. Blood. 2015;126:2812.